Soy isoflavone delays the progression of thioacetamide-induced liver fibrosis in rats

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 3, 2011, Pages 341-349

  Li, Jian Fang ^a,b   Chen, Bi Cheng ^c   Lai, Dan Dan ^b   Jia, Zeng Rong ^a   Andersson, Roland ^d   Zhang, Bo ^a   Yao, Jian Gao ^a   Yu, Zhen ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Isoflavone; liver fibrosis; rats; thioacetamide

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGENASE 3; CYTOKINE; ISOFLAVONE; PLATELET DERIVED GROWTH FACTOR BB; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CELL STRUCTURE; DISEASE COURSE; ELECTRON MICROSCOPY; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL;

EID: 79751504859     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.525662     Document Type: Article

References (35)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-18. (Pubitemid 40385459)
2. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
3. Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver trans-plantation. Dig Liver Dis 2005;37:349-56. (Pubitemid 44356038)
4. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131:1728-34. (Pubitemid 350077474)
5. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004;36:231-42. (Pubitemid 41115470)
6. Kurzer MS. Phytoestrogen supplement useby women.JNutr 2003;133:1983S-1986S.
7. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98: 1275-84. (Pubitemid 44530723)
8. Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res 2006;66:1241-9. (Pubitemid 43165996)
9. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascularhealth: asummaryofastatementforprofessionals from the american heart association nutrition committee. Arter-ioscler Thromb Vasc Biol 2006;26:1689-92. (Pubitemid 44305320)
10. Lin CY, Tsai CY, Lin SH. Effects of soy components on blood and liver lipids in rats fed high-cholesterol diets. World J Gastroenterol 2005;11:5549-52.
11. Iqbal MJ, Yaegashi S, Ahsan R, Lightfoot DA, Banz WJ. Differentially abundant mRNAs in rat liver in response to diets containing soy protein isolate. Physiol Genomics 2002; 11:219-26. (Pubitemid 37128738)
12. Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F, Ozercan IH. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007;52:2006-14. (Pubitemid 47024653)
13. Mizushige T, Mizushige K, Miyatake A, Kishida T, Ebihara K. Inhibitory effects of soy isoflavones on cardio-vascular collagen accumulation in rats. J Nutr Sci Vitaminol (Tokyo) 2007;53:48-52. (Pubitemid 46623917)
14. Strnad P, Tao GZ, Zhou Q, Harada M, Toivola DM, Brunt EM, Omary MB. Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroen-terology 2008;134:1169-79. (Pubitemid 351451981)
15. Moal F, Chappard D, Wang J, Vuillemin E, Michalak-Provost S, Rousselet MC, Oberti F, Cales P. Fractal dimen-sion can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology 2002;36:840-9.
16. Lee TH, Jawan B, Chou WY, Lu CN, Wu CL, Kuo HM, Concejero AM, Wang CH. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med 2006;8:764-72.
17. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28: 439-46. (Pubitemid 28133548)
18. Vera M, Nieto N. Hepatic stellate cells and alcoholic liver disease. Rev Esp Enferm Dig 2006;98:674-84. (Pubitemid 350259141)
19. Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmouliere A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006;38:135-51. (Pubitemid 41619443)
20. Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003;28:105-12. (Pubitemid 36790453)
21. Liu XJ, Yang L, Mao YQ, Wang Q, Huang MH, Wang YP, Wu HB. Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells. World J Gastroenterol 2002;8:739-45. (Pubitemid 34918674)
22. Gressner AM, Weiskirchen R. Modern pathogenetic con-cepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10:76-99. (Pubitemid 44874293)
23. Hoch RV, Soriano P. Rolesof PDGFin animal development. Development 2003;130:4769-84.
24. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201:925-35. (Pubitemid 40524462)
25. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79: 1283-316. (Pubitemid 29473317)
26. Kershenobich Stalnikowitz D, Weissbrod AB. Liver fibrosis and inflammation. A review. Ann Hepatol 2003;2:159-63.
27. Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Trans-genic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling. Proc Am Thorac Soc 2006;3:418-23. (Pubitemid 44033356)
28. Khan R, Sheppard R. Fibrosis in heart disease: understand-ing the role of transforming growth factor-beta in cardiomy-opathy, valvular disease and arrhythmia. Immunology 2006; 118:10-24.
29. Morris-Stiff G. TGFbeta-1 and the development of chronic graft nephropathy: relative roles of gene, mRNA and protein. Ann R Coll Surg Engl 2005;87:326-30. (Pubitemid 41762029)
30. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997;26:1213-19. (Pubitemid 27346632)
31. Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999;14:138-45. (Pubitemid 29092871)
32. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001;36: 399-406. (Pubitemid 32633448)
33. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating matrix metal-loproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99:271-9. (Pubitemid 38279869)
34. El-Gindy I, El Rahman AT, El-Alim MA, Zaki SS. Diag-nostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive mar-kers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol 2003;10:27-35.
35. Afdhal N. Can serum markers be used to reliably detect liver fibrosis? Nat Clin Pract Gastroenterol Hepatol 2005;2: 132-3. (Pubitemid 40812509)